Breaking News
Get 45% Off 0
🤖 Are you in? These 5 AI-picked stocks are up 15%+
Read article

Stock Markets Analysis & Opinion

Contribute
Zacks Investment Research
Mid-Cap Growth ETFs For A Roller-Coaster Market By Zacks Investment Research - Feb 08, 2018

After a prolonged calm period, volatility roared back into the market with the sharp rise in Treasury yields, which led to the bloodbath in the stock market this week. This pushed the major indices...

Zacks Investment Research
Franklin's (BEN) January AUM Up, Hybrid & Equity Assets Rise By Zacks Investment Research - Feb 08, 2018

Franklin Resources Inc. (NYSE:BEN) has announced preliminary assets under management (AUM) by its subsidiaries of $770.8 billion for January 2018. Results display 2.3% rise from $753.8 billion...

Zacks Investment Research
Watsco (WSO) Q4 Earnings & Sales Miss Estimates, Stock Down By Zacks Investment Research - Feb 08, 2018

Watsco, Inc. (NYSE:WSO) posted adjusted earnings per share of 90 cents in fourth-quarter 2017, up 11% year over year. Earnings, however, missed the Zacks Consensus Estimate of $1.00. Evidently,...

Zacks Investment Research
Mettler-Toledo (MTD) Q4 Earnings & Revenues Beat Estimates By Zacks Investment Research - Feb 08, 2018

Mettler-Toledo International Inc. (NYSE:MTD) reported impressive fourth-quarter 2017 results. The company reported adjusted earnings of $5.97 per share, which beat the Zacks Consensus Estimate by 3...

Zacks Investment Research
Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study By Zacks Investment Research - Feb 08, 2018

GlaxoSmithKline (NYSE:GSK) along with partner Pfizer, Inc. (NYSE:PFE) announced that their HIV-focused joint venture company, ViiV Healthcare, has initiated a phase III program to evaluate its...

Zacks Investment Research
Ventas' (VTR) Q4 FFO In Line With Estimates, Revenues Beat By Zacks Investment Research - Feb 08, 2018

Ventas, Inc. (NYSE:VTR) reported fourth-quarter 2017 normalized funds from operations (FFO) of $1.03 per share, in line with the Zacks Consensus Estimate. The figure also matched the year-ago...

Zacks Investment Research
Domtar's (UFS) Q4 Earnings Miss Estimates As Costs Flare Up By Zacks Investment Research - Feb 08, 2018

Domtar Corporation (TO:UFS) reported mixed fourth-quarter 2017 results.Earnings/Revenues Quarterly adjusted earnings came in at 64 cents per share, missing the Zacks Consensus Estimate of 69 cents....

Zacks Investment Research
QIAGEN Strong On Molecular Diagnostics, Competition Rife By Zacks Investment Research - Feb 08, 2018

On Feb 6, we issued an updated research report on QIAGEN N.V. (NYSE:QGEN) . The stock carries a Zacks Rank #3 (Hold).This Netherlands-based molecular diagnostics provider offers innovative...

Zacks Investment Research
Occidental (OXY) Q4 Earnings: Will It Beat Estimates Again? By Zacks Investment Research - Feb 08, 2018

We expect Occidental Petroleum Corporation (NYSE:OXY) to beat earnings estimates when it releases fourth-quarter 2017 financial results after the market closes on Feb 13. In the third quarter, the...

Zacks Investment Research
Alnylam's (ALNY) Q4 Earnings And Revenues Top Estimates By Zacks Investment Research - Feb 08, 2018

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) incurred a loss of $1.20 per share in the fourth quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $1.38. However, the figure was...

Zacks Investment Research
Hologic (HOLX) Q1 Earnings & Revenues Top, Margins Down By Zacks Investment Research - Feb 08, 2018

Hologic, Inc. (NASDAQ:HOLX) reported first-quarter fiscal 2018 adjusted earnings per share (EPS) of 55 cents, up 5.8% year over year. Moreover, adjusted EPS beat the Zacks Consensus Estimate by...

Zacks Investment Research
5 Best PEG Stocks Value Investors Love By Zacks Investment Research - Feb 08, 2018

With externalities impacting stock markets every second day, investors with varied risk appetite prefer to go for value investing. In the event of a market crash, investors often end up to selling...

Zacks Investment Research
Teva (TEVA) Q4 Earnings Top, Stock Tanks On Weak 2018 View By Zacks Investment Research - Feb 08, 2018

Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported fourth-quarter 2017 earnings of 93 cents per share, which beat the Zacks Consensus Estimate of 81 cents per share and came ahead of the...

Zacks Investment Research
New Strong Buy Stocks For February 9th By Zacks Investment Research - Feb 08, 2018

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:Air Transport Services Group, Inc. (ATSG): This company that provides aircraft leasing, airline operations, and aircraft...

Alex Newman
Can iRobot stand up to competition? By Alex Newman - Feb 08, 2018

Vacuum cleaner company iRobot Corporation (NASDAQ:IRBT) has had a tumultuous month and now has been hit hard by its latest earnings report. As the Financial Times and other sources report, iRobot saw...

Continue with Apple
Continue with Google
or
Sign up with Email